Pentixapharm Secures EUR 6.77 Million from Glycotope Assets

Berlin-based Pentixapharm AG has announced a significant financial gain, receiving EUR 6.77 million for intangible assets formerly associated with Glycotope. These assets were acquired as part of Pentixapharm’s purchase of Glycotope’s target discovery business in July 2024. The transaction involved undisclosed Asian pharmaceutical and biotech companies and is expected to be finalized within 2024.

This deal reduces Pentixapharm’s obligations from the earn-out agreements linked to the acquisition. Although it doesn't markedly impact Pentixapharm's financial losses for 2024, it underlines the pharmaceutical sector's confidence in the company's strategic assets. Pentixapharm's acquisition includes preclinical antibodies, a tumor target database, and essential IP for further scientific exploration.